265. 脂肪萎縮症
[臨床試験数:109,薬物数:164(DrugBank:59),標的遺伝子数:26,標的パスウェイ数:94

Searched query = "Lipodystrophy", "Berardinelli-Seip syndrome", "Lawrence syndrome", "Barraquer-Simons syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
16 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01263717
(ClinicalTrials.gov)
December 201016/12/2010Effects of Growth Hormone Releasing Hormone in HIVEffects of Growth Hormone Releasing Hormone on Fat Redistribution, Cardiovascular Indices, and Growth Hormone Secretion in HIV LipodystrophyHIV;HIV LipodystrophyDrug: tesamorelin;Drug: placeboMassachusetts General HospitalNULLCompleted18 Years65 YearsAll54N/AUnited States
2NCT00795210
(ClinicalTrials.gov)
February 200920/11/2008Effects of Short-term Growth Hormone in HIV-infected PatientsEffects of Short-term Growth Hormone in HIV-infected PatientsHIV LipodystrophyDrug: Growth hormone;Drug: Growth Hormone Releasing HormoneMassachusetts General HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed18 Years60 YearsAll25N/AUnited States
3EUCTR2007-003233-16-ES
(EUCTR)
11/12/200722/10/2007A multicenter, double-blind, randomized, placebo-controlled extension study assessing the efficacy and long-term safety of a 2mg dose of TH9507, a growth hormone releasing factor analog, in HIV subjects with excess abdominal fat accumulation.Estudio de extesión, multicéntrico, doble ciego, aleatorizado, controlado con placebo para evaluar la eficacia y seguridad a largo plazo de una dosis de 2 mg de TH9507, un análogo del factor liberador de la hormona de crecimiento, en sujetos con VIH con acumulación excesiva de grasa abdominal.A multicenter, double-blind, randomized, placebo-controlled extension study assessing the efficacy and long-term safety of a 2mg dose of TH9507, a growth hormone releasing factor analog, in HIV subjects with excess abdominal fat accumulation.Estudio de extesión, multicéntrico, doble ciego, aleatorizado, controlado con placebo para evaluar la eficacia y seguridad a largo plazo de una dosis de 2 mg de TH9507, un análogo del factor liberador de la hormona de crecimiento, en sujetos con VIH con acumulación excesiva de grasa abdominal. Lipodistrofia asociada a VIH.HIV-associated lipodystrophy.
MedDRA version: 9.1;Level: LLT;Classification code 10024608;Term: Lipodystrophy
Product Name: Tesamorelin
Product Code: TH9507
INN or Proposed INN: Tesamorelin
Other descriptive name: [N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate
Theratechnologies Inc.NULLNot RecruitingFemale: yes
Male: yes
300United Kingdom;Belgium;France;Spain
4EUCTR2007-003233-16-GB
(EUCTR)
29/11/200702/08/2007A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation.A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation. HIV-associated lipodystrophy
MedDRA version: 9.1;Level: LLT;Classification code 10024608;Term: Lipodystrophy
Theratechnologies Inc.NULLNot Recruiting Female: yes
Male: yes
300Phase 3France;Spain;Belgium;United Kingdom
5EUCTR2007-003233-16-FR
(EUCTR)
19/09/200731/07/2007A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation.A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation. HIV-associated lipodystrophy
MedDRA version: 9.1;Level: LLT;Classification code 10024608;Term: Lipodystrophy
Product Name: Tesamorelin
Product Code: TH9507
INN or Proposed INN: Tesamorelin
Other descriptive name: [N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate
Theratechnologies Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
300United Kingdom;Belgium;France;Spain
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2007-003233-16-BE
(EUCTR)
05/09/200722/08/2007A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation.A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation. HIV-associated lipodystrophy
MedDRA version: 9.1;Level: LLT;Classification code 10024608;Term: Lipodystrophy
Product Name: Tesamorelin
Product Code: TH9507
INN or Proposed INN: Tesamorelin
Other descriptive name: [N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate
Theratechnologies Inc.NULLNot RecruitingFemale: yes
Male: yes
300United Kingdom;Belgium;France;Spain
7NCT00608023
(ClinicalTrials.gov)
August 200723/1/2008TH9507 Extension Study in Patients With HIV- Associated LipodystrophyA Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Subjects With Excess Abdominal Fat AccumulationLipodystrophy;HIV InfectionsDrug: Tesamorelin;Drug: Placebo for TesamorelinTheratechnologiesNULLCompleted18 Years65 YearsAll263Phase 3United States;Belgium;Canada;France;Spain;United Kingdom
8EUCTR2006-005444-88-DE
(EUCTR)
21/06/200714/08/2007A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat AccumulationA Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation HIV-associated lipodystrophy
MedDRA version: 8.1;Level: LLT;Classification code 10024608;Term: Lipodystrophy
Product Name: TH9507
Product Code: TH9507
Other descriptive name: [N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate
Theratechnologies Inc.NULLNot RecruitingFemale: yes
Male: yes
400United Kingdom;Germany;France;Spain
9EUCTR2006-005444-88-GB
(EUCTR)
08/05/200726/01/2007A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat AccumulationA Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation HIV-associated lipodystrophy
MedDRA version: 8.1;Level: LLT;Classification code 10024608;Term: Lipodystrophy
Theratechnologies Inc.NULLNot Recruiting Female: yes
Male: yes
400Phase 3France;Spain;Belgium;Germany;United Kingdom
10EUCTR2006-005444-88-ES
(EUCTR)
25/04/200703/03/2010A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation.Estudio aleatorizado, doble ciego, multicéntrico y controlado por placebo, en el que se evalúa la eficacia y la seguridad de una dosis de 2 mg de TH9507, una sustancia análoga al factor liberador de la hormona del crecimiento, para pacientes de VIH con acumulación excesiva de tejido adiposo abdominal.A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation.Estudio aleatorizado, doble ciego, multicéntrico y controlado por placebo, en el que se evalúa la eficacia y la seguridad de una dosis de 2 mg de TH9507, una sustancia análoga al factor liberador de la hormona del crecimiento, para pacientes de VIH con acumulación excesiva de tejido adiposo abdominal. HIV-associated lipodystrophyLipodistrofia asociada al VIH
MedDRA version: 8.1;Level: LLT;Classification code 10024608;Term: Lipodystrophy
Product Name: TH9507
Product Code: TH9507
Other descriptive name: [N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate
Theratechnologies Inc.NULLNot RecruitingFemale: yes
Male: yes
400Germany;United Kingdom;France;Spain
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2006-005444-88-FR
(EUCTR)
15/02/200711/01/2007A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat AccumulationA Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation HIV-associated lipodystrophy
MedDRA version: 8.1;Level: LLT;Classification code 10024608;Term: Lipodystrophy
Product Name: TH9507
Product Code: TH9507
Other descriptive name: [N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate
Theratechnologies Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
400Germany;United Kingdom;France;Spain
12EUCTR2006-005444-88-BE
(EUCTR)
16/01/200721/12/2006A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat AccumulationA Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation HIV-associated lipodystrophy
MedDRA version: 8.1;Level: LLT;Classification code 10024608;Term: Lipodystrophy
Product Name: TH9507
Product Code: TH9507
Other descriptive name: [N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate
Theratechnologies Inc.NULLNot RecruitingFemale: yes
Male: yes
400France;Spain;Belgium;Germany;United Kingdom
13NCT00123253
(ClinicalTrials.gov)
June 200520/7/2005TH9507 in Patients With HIV-Associated LipodystrophyA Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Patients With Excess of Abdominal Fat AccumulationHIV Infections;LipodystrophyDrug: TH9507TheratechnologiesNULLCompleted18 Years65 YearsBoth412Phase 3United States;Canada
14NCT00130286
(ClinicalTrials.gov)
March 200512/8/2005Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin ResistanceRandomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Recombinant Human Growth Hormone and/or Rosiglitazone in the Treatment of Human Immunodeficiency Virus-Associated Visceral Adiposity and Insulin ResistanceHIV-Associated Lipodystrophy Syndrome;Insulin Resistance;HIV Infections;Metabolic Syndrome X;Body Weight ChangesDrug: Rosiglitazone;Drug: Recombinant human growth hormone + rosiglitazoneWeill Medical College of Cornell UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed18 Years65 YearsAll77Phase 1;Phase 2United States
15NCT00119769
(ClinicalTrials.gov)
February 20057/7/2005The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected PatientsThe Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients on Highly Active Antiretroviral Therapy (HAART)HIV Infections;LipodystrophyDrug: Placebo;Drug: Genotropin (human recombinant Growth hormone)Hvidovre University HospitalPfizerCompleted21 Years60 YearsMale46Phase 4Denmark
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT00100698
(ClinicalTrials.gov)
January 20044/1/2005Physiologic Growth Hormone Effects in HIV LipodystrophyPhysiologic Growth Hormone Effects in HIV LipodystrophyAIDS;HIV InfectionsDrug: recombinant human growth hormone;Drug: placeboMassachusetts General HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed18 Years60 YearsAll56N/AUnited States